Table 1.
WHO, 1998 [4] | EGIR, 1999 [6] | NCEP ATPIII, 2001 [7] | IDF, 2005 [1] | |
---|---|---|---|---|
Insulin resistance | Known dysglycaemia (diabetes/IFG/IGT) and/or insulin resistance | Insulin resistance | – | – |
Plus ≥2 of the following: | Plus ≥2 of the following: | ≥3 of the following: | ||
Obesity | BMI >30 kg/m2 or waist-to-hip ratio for men: >0.9; for women: >0.85 | Waist circumference for men: ≥94 cm; for women: ≥80 cm | Waist circumference for men: >102 cm; for women: >88 cm | Waist circumference for men: ≥94 cm; for women: ≥80 cm (a prerequisite) |
Plus ≥2 of the following: | ||||
Dyslipidaemia | TG: ≥1.7 mmol/L; or HDL-C for men: <0.9 mmol/L; for women: <1.0 mmol/L | TG: >2.0 mmol/L; or HDL-C: <1.0 mmol/L | TG: ≥1.7 mmol/L | TG: ≥1.7 mmol/L |
Low HDL-C: <1.0 mmol/L in men; or <1.3 mmol/L in women | Low HDL-C: <1.0 mmol/L in men; or <1.3 mmol/L in women | |||
Hypertension | On treatment or BP: ≥160/ 90 mmHga | On treatment or BP ≥140/ 90 mmHg | On treatment or BP ≥130/ 85 mmHg | On treatment or BP ≥130/ 85 mmHg |
Microalbuminuria | Urinary albumin excretion ≥20 μg/min or albumin:creatinine ratio ≥20 mg/g | – | – | – |
Dysglycaemia | Fasting PG ≥6.1 mmol/L | Fastingb PG ≥6.1 mmol/L | Fasting PG ≥5.6 mmol/L |
WHO, World Health Organization; EGIR, European Group for the study of Insulin Resistance; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; AACE, American Association of Clinical Endocrinology; IDF, International Diabetes Federation; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; BMI, body mass index; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure; PG, plasma glucose; OGTT, oral glucose tolerance test.
aBP cutoff value of the WHO 1998 criteria was revised to 140/90 mmHg in 1999 [5].
bFasting PG cutoff level of the NCEP ATPIII 2001 criteria was modified to 5.6 mmol/L in 2005 [8].